Table 4 Studies of treatment with interferon-α for prevention of HCC in patients with hepatitis B-related cirrhosis
Author [reference] | Country | Type of study | Interferon regimen (duration in weeks) | Follow-up (range) in months | Sample size | Rate of HCC (n/n) | Significance |
|---|---|---|---|---|---|---|---|
Oon, 1992 [183] | Singapore | NRCT, P | 10 MU daily, 10 days/month (12) | 12 (12–60) | T 600 C 180 | T: 0/600 (0%) C: 10/180 (5.6%) | Significant |
Mazzella, 1996 [184] | Italy | NRCT, P | 10 MU tiw (26) | 49 (12–119) | T 34 C 28 | T: 2/34 (5.9%) C: 4/28 (14.3%) | Not significant |
Fattovich, 1997 [185] | Europe | NRCT, P | ≥ 300 MU (12–52) | 84 (80–92) | T 40 C 50 | T: 3/40 (7.5%) C: 4/50 (8.0%) | Not significant |
Ikeda, 1998 [186] | Japan | NRCT, P | 12 MU/wk (26) | 84 (6–168) | T 94 C 219 | T: 10/94 (10.6%) C: 51/219 (23.3%) | Significant |
IHCSG, 1998 [187] | Argentina, Germany, Italy, Saudi Arabia | NRCT, P | 9–30 MU/wk for 3–30 months | (36–250) | T 49 C 97 | T: 8/49 (16.3%) C: 18/97 (18.6%) | Not significant |
Benvegnù, 1998 [188] | Italy | NRCT, P | 6–10 MU (20–26) | 72 | T 10 C 18 | T: 0/10 (0%) C: 4/18 (22.2%) | Not significant |
Di Marco, 1999 [189] | Italy | NRCT, P | 655 MU | 93 (6–180) | T 26 C 60 | T: 2/26 (7.7%) C: 6/60 (10%) | NR |